Please assess the completion status of the following clinical trial:

Trial Title: Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18，Pathologically proven non small cell lung cancer~  * Adenocarcinoma，No-drive gene mutaion (EGFR、ALK、ROS1） by NGS~ * Squamous cell carcinoma，no gene detection~ * Progress after second line~ * PS score \>2~Exclusion Criteria:~* Patients received apatinib or Vinorelbine treatment before~* EGFR, ALK or ROS1 mutation~* Patients with contraindication of chemotherapy~* Pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apatinib Combined With Vinorelbine (Type: EXPERIMENTAL): Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).